OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
279658

Pharmarise Holdings Corp

Drug RetailersVerified

Pharmarise Holdings Corp has a liquidity position that is medium, with a current ratio of 1.1 and a debt-to-equity ratio of 2.08, indicating a relatively high leverage position. The company's cash and equivalents amount to 4,911,000,000 JPY, but this is offset by long-term debt of 14,279,000,000 JPY, resulting in a net cash position that is negative after subtracting total debt. Profitability metrics show a return on equity of -6% and a return on assets of -1.29%, both of which are below the industry median for Drug Retailers. The company reported a net loss of 412,000,000 JPY, with an operating income of only 120,000,000 JPY, indicating a weak performance in generating profit from operations. The company's revenue is distributed across five business segments, with the Dispensing Pharmacy segment being the primary source of operations. The Merchandising segment includes cosmetics sales, convenience store management, and drug store management. The Medical Document Storage and Management segment handles the storage of medical records, while the Medical Mall Management segment operates at JR Tower Office Plaza Sapporo. The Others segment includes temporary staffing and stationery sales. Growth trajectory appears to be constrained, with the company reporting a net loss in the latest period. The operating cash flow is 1,313,000,000 JPY, and free cash flow is 142,000,000 JPY, suggesting limited capacity for reinvestment or debt reduction. The capital expenditure of -702,000,000 JPY indicates a reduction in capital spending. Risk factors include a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to meet short-term obligations. The dilution potential is low, with no significant changes in shares outstanding between basic and diluted shares. Recent events include the latest actual EPS of -32.42 JPY and revenue of 63,508,000,000 JPY, as reported by analysts. These figures reflect the company's current financial performance and expectations.

30-day price · 2796+10.00 (+1.9%)
Low$518.00High$534.00Close$531.00As of21 May, 00:00 UTC
Profile
CompanyPharmarise Holdings Corp
Ticker2796.T
SectorConsumer Non-Cyclicals
BusinessFood & Drug Retailing
Industry groupFood & Drug Retailing
IndustryDrug Retailers
AI analysis

Business. Pharmarise Holdings Corp operates as a Japan-based holding company primarily engaged in dispensing pharmacy businesses, including operations in cosmetics sales, convenience store management, and medical document storage.

Classification. Pharmarise is classified under the Consumer Non-Cyclicals economic sector, Food & Drug Retailing business sector, and Drug Retailers industry with a confidence level of 0.92.

Pharmarise Holdings Corp has a liquidity position that is medium, with a current ratio of 1.1 and a debt-to-equity ratio of 2.08, indicating a relatively high leverage position. The company's cash and equivalents amount to 4,911,000,000 JPY, but this is offset by long-term debt of 14,279,000,000 JPY, resulting in a net cash position that is negative after subtracting total debt. Profitability metrics show a return on equity of -6% and a return on assets of -1.29%, both of which are below the industry median for Drug Retailers. The company reported a net loss of 412,000,000 JPY, with an operating income of only 120,000,000 JPY, indicating a weak performance in generating profit from operations. The company's revenue is distributed across five business segments, with the Dispensing Pharmacy segment being the primary source of operations. The Merchandising segment includes cosmetics sales, convenience store management, and drug store management. The Medical Document Storage and Management segment handles the storage of medical records, while the Medical Mall Management segment operates at JR Tower Office Plaza Sapporo. The Others segment includes temporary staffing and stationery sales. Growth trajectory appears to be constrained, with the company reporting a net loss in the latest period. The operating cash flow is 1,313,000,000 JPY, and free cash flow is 142,000,000 JPY, suggesting limited capacity for reinvestment or debt reduction. The capital expenditure of -702,000,000 JPY indicates a reduction in capital spending. Risk factors include a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to meet short-term obligations. The dilution potential is low, with no significant changes in shares outstanding between basic and diluted shares. Recent events include the latest actual EPS of -32.42 JPY and revenue of 63,508,000,000 JPY, as reported by analysts. These figures reflect the company's current financial performance and expectations.
Key takeaways
  • Pharmarise Holdings Corp is a Japan-based holding company with a primary focus on dispensing pharmacy businesses.
  • The company's liquidity position is medium, with a current ratio of 1.1 and a debt-to-equity ratio of 2.08.
  • Profitability is weak, with a return on equity of -6% and a return on assets of -1.29%.
  • Revenue is spread across five business segments, with the Dispensing Pharmacy segment being the primary source of operations.
  • Growth is constrained by a net loss and limited free cash flow.
  • Risk factors include a medium liquidity risk and a low dilution risk.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$63.51B
Gross profit$8.97B
Operating income$120.0M
Net income-$412.0M
R&D
SG&A
D&A
SBC
Operating cash flow$1.31B
CapEx-$702.0M
Free cash flow$142.0M
Total assets$31.92B
Total liabilities$25.05B
Total equity$6.87B
Cash & equivalents$4.91B
Long-term debt$14.28B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$63.51B$120.0M-$412.0M$142.0M
FY-1$54.47B$209.0M-$351.0M$82.0M
FY-2
FY-3$51.61B$1.30B$448.0M$1.17B
FY-4$52.32B$878.0M$426.0M$1.08B
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$31.92B$6.87B$4.91B
FY-1$29.49B$7.36B$7.15B
FY-2
FY-3$23.75B$6.61B$3.99B
FY-4$24.72B$6.22B$4.60B
PeriodOCFCapExFCFSBC
FY0$1.31B-$702.0M$142.0M
FY-1$2.71B-$619.0M$82.0M
FY-2
FY-3$713.0M-$466.0M$1.17B
FY-4$1.94B-$552.0M$1.08B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$16.95B$179.0M-$125.0M
FQ-1
FQ-2$16.75B$153.0M-$19.0M
FQ-3$16.93B$37.0M-$141.0M
FQ-4$16.04B-$21.0M-$156.0M
FQ-5
FQ-6$15.23B$51.0M-$132.0M
FQ-7$13.79B-$596.0M-$529.0M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$31.43B$6.69B$2.24B
FQ-1
FQ-2$30.17B$6.62B$2.12B
FQ-3$31.92B$6.87B$4.91B
FQ-4$31.10B$6.95B$2.24B
FQ-5
FQ-6$27.86B$7.00B$4.10B
FQ-7$29.49B$7.36B$7.15B
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3$1.31B-$702.0M
FQ-4
FQ-5
FQ-6
FQ-7$2.71B-$619.0M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$6.87B
Net cash-$9.37B
Current ratio1.1
Debt/Equity2.1
ROA-1.3%
ROE-6.0%
Cash conversion-3.2%
CapEx/Revenue-1.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Food & Drug Retailing · cohort 234 companies
Metric2796Activity
Op margin0.2%2.8% medp25 0.9% · p75 5.9%bottom quartile
Net margin-0.6%1.8% medp25 0.3% · p75 3.6%bottom quartile
Gross margin14.1%24.1% medp25 13.8% · p75 31.4%below median
CapEx / revenue-1.1%-2.0% medp25 -3.8% · p75 -1.0%above median
Debt / equity208.0%56.0% medp25 14.0% · p75 113.8%top quartile
Observations
IR observations
Last actual EPS-32.42 JPY
Last actual revenue63,508,000,000 JPY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 13:05 UTC#24b7bc6e
Market quoteclose JPY 525.00 · shares 0.01B diluted
no public URL
2026-05-05 03:19 UTC#91a12bae
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 13:07 UTCJob: 1e6c9219